Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy

Background To evaluate the efficacy of bevacizumab on reduction of the enucleation rate and control of intraocular pressure (IOP) in neovascular glaucoma (NVG)-complicating proton beam therapy for UM and to identify the determinants of the efficacy of bevacizumab.